Back to Search Start Over

Anthracycline cardiotoxicity: current methods of diagnosis and possible role of 18F-FDG PET/CT as a new biomarker

Authors :
Mônica M. C. Becker
Gustavo F. A. Arruda
Diego R. F. Berenguer
Roberto O. Buril
Daniela Cardinale
Simone C. S. Brandão
Source :
Cardio-Oncology. 9
Publication Year :
2023
Publisher :
Springer Science and Business Media LLC, 2023.

Abstract

Despite advances in chemotherapy, the drugs used in cancer treatment remain rather harmful to the cardiovascular system, causing structural and functional cardiotoxic changes. Positron-emission tomography associated with computed tomography (PET/CT) has emerged like a promising technique in the early diagnosis of these adverse drug effects as the myocardial tissue uptake of fluorodeoxyglucose labeled with fluorine-18 (18F-FDG), a glucose analog, is increased after their use. Among these drugs, anthracyclines are the most frequently associated with cardiotoxicity because they promote heart damage through DNA breaks, and induction of an oxidative, proinflammatory, and toxic environment. This review aimed to present the scientific evidence available so far regarding the use of 18F-FDG PET/CT as an early biomarker of anthracycline-related cardiotoxicity. Thus, it discusses the physiological basis for its uptake, hypotheses to justify its increase in the myocardium affected by anthracyclines, importance of 18F-FDG PET/CT findings for cardio-oncology, and primary challenges of incorporating this technique in standard clinical oncology practice.

Details

ISSN :
20573804
Volume :
9
Database :
OpenAIRE
Journal :
Cardio-Oncology
Accession number :
edsair.doi...........34ddcbdd46d04f6f44feef32635807ef
Full Text :
https://doi.org/10.1186/s40959-023-00161-6